- Population of cancer patients with limited treatment options
- Conversion of compassionate use scheme into formal study
- Additional to existing clinical program
- Designed to provide data for future regulatory submission
Sydney, 24 May 2017: In response to growing demand for the Company’s Compassionate Use Program, Noxopharm has decided to make its experimental anti-cancer drug, NOX66, available for the treatment of rare cancers in a formal clinical trial setting.
For further information please download PDF attached:
Download this document
